A retrospective multicenter cohort study assessing the outcomes after the resumption of immune checkpoint inhibitor therapy in patients with melanoma with resolved high‐grade immune checkpoint inhibitor hepatitis
Latest Information Update: 08 Sep 2020
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 08 Sep 2020 New trial record
- 05 Sep 2020 Results published in the Cancer